ENZN 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-03

• Selling, general and administrative expenses consist primarily of personnel-related expenses, including recruiting costs, salaries, bonuses, benefits, and equity-based compensation, for individuals in Viskase’s executive, finance, operations, human resources, business development and other administr…

• Loss from operations totaled approximately $2.0 million for the three months ended June 30, 2026, compared to $2.6 million for the three months ended June 30, 2025. The decrease in operating loss of $0.6 million or (23.4)% was primarily driven by the decrease in selling, general and administrative e…

• North America operating income has improved $0.6 million due to selling, general and administrative.

• Results of Operations – Comparison of Six Months Ended June 30, 2026 and 2025

• The following table summarizes Viskase’s annual condensed consolidated statement of operations for the periods presented (in thousands):

相对上期删除的文字 · 来源:10-Q · 2026-05-04

• Immediately following the Merger, Viskase Companies converted into a limited liability company under Delaware law, and the Company changed its name from “Enzon Pharmaceuticals, Inc.” to “Viskase Holdings, Inc.” References herein to the Company refer to Viskase Holdings, Inc., which operates it busin…

• Selling, general and administrative expenses consist primarily of personnel-related expenses, including recruiting costs, salaries, bonuses, benefits, and equity-based compensation, for individuals in Viskase’s executive, finance, operations, human resources, business

• development and other administrative functions. Other selling, general and administrative expenses include legal fees relating to corporate matters and patent-related activities, insurance costs, information technology, and professional and consulting fees associated with accounting, audit, tax and …

• Loss from operations totaled approximately $4.3 million for the three months ended March 31, 2026, compared to $14.4 million for the three months ended March 31, 2025. The decrease in operating loss of $10.1 million or (69.9)% was primarily driven by asset impairment expense of $12.1 million recorde…

• North America operating income has improved $11.8 million due to lower asset impairment and restructuring expense of $16.4 million offset by a decrease in gross profit due to lower sales volume. EMEA operating income is lower by $1.6 million compared to March 31, 2025 due to lower gross profit on sa…